- 14 March
-
At the end of the last year, Novouralsk-based Medsintez Plant turned 20 years old. Alexander Petrov, Chairman of the plant's Board of Directors, told Regions of Russia about the impressive successes that the company has achieved over the years and its ambitious plans for the future.
- 22 January
-
In 2023, the Medsintez Plant, in collaboration with the Promomed Group of Companies, launched the production of a full cycle of hypoglycemic drugs Enligria (liraglutide) and Quincenta (semaglutide) used in treating type II diabetes mellitus, including in patients with obesity and overweight or cardiovascular disease. The preparations are available in the most convenient and familiar for patients dosage form – a disposable prefilled injection and have already been supplied to pharmacies.
- 13 December
-
Medsintez Plant LLC presented the latest biotechnological developments of pharmaceuticals at the largest international scientific and practical forum in the field of medicine and health care Russian Health Care Week — 2023 held from December 4 to December 8 in Moscow. The main purpose of the Forum is to facilitate the implementation of the national projects “Healthcare” and “Demography”, “Tourism and Hospitality Industry”, the federal project “Development of Medical Services Export”, as well as summarizing the results of the Year of Science and Technology in Medicine.
- 04 October
-
On September 27, as part of the business program of the GMP conference with international participation, Alexander Petrov, Chairman of the Board of Directors of Medsintez Plant LLC, took part in a Plenary Session on the issues of regulating the circulation of medicines in Russia and the EAEU, developing import independence, and increasing export potential. The session was attended by representatives of the Ministry of Industry and Trade of the Russian Federation, the Minister of Health of the Republic of Nicaragua, the WHO Representative in Russia, a Representative of the Serbian Ministry of Health and other Russian and foreign experts. Mr. Petrov spoke about the problems that Russian pharmaceutical companies face when entering international markets and suggested possible solutions.
- Home
- Cluster members
- Institute of Chemical Engineering, Ural Federal University
Institute of Chemical Engineering, Ural Federal University
Institute of Chemical Engineering is one of leading institutes of the Ural Federal University, which does not stand still, constantly develops and keeps up to date.
Key competencies of the institute in the field of medicinal chemistry and pharmaceutical technologies are concentrated in departments, scientific laboratories, as well as in the Scientific, Educational and Innovation Center of Chemical and Pharmaceutical Technologies. A unique university in the Urals in terms of leading world-class scientific schools, technical equipment, laboratories, outstanding teachers and. scientists, educational programs. Pharmaceutical engineering is the hallmark of the Institute.
The Institute carries out active scientific and innovative work in the field of medical and pharmaceutical chemistry in cooperation with leading Russian and foreign centers. Graduates of the Institute work at chemical industry enterprises, enterprises manufacturing equipment for chemical industry, pharmaceuticals, in environmental protection institutions, in research and designing departments of biotechnological and microbiological enterprises, in production of medicinal substances, biopolymers using modern biotechnological methods, implementation of medical drug formulations and methods of quality control of raw materials, intermediate products and finished products, as well as in state regulatory organizations.
